The Biological Backbone: Relmada's Pipeline Pivot Takes the Stage in London

CORAL GABLES, Fla. – November 04, 2026

Much like the invisible digital networks that dictate the flow of modern cities, the biotechnology sector is governed by an underlying architecture of clinical data, regulatory pathways, and capital deployment. When a foundational element of that architecture shifts, the entire system must be re-engineered. Relmada Therapeutics, Inc. (Nasdaq: RLMD) is currently navigating precisely this kind of structural pivot. Today, the clinical-stage biotechnology company announced that its executive leadership will present at the Jefferies Global Healthcare Conference in London, scheduled for November 16 through November 19, 2026.

Chief Executive Officer Sergio Traversa and Chief Financial Officer Maged Shenouda are slated to host a fireside chat on Monday, November 16, at 12:00 PM GMT (7:00 AM ET), alongside a series of one-on-one meetings with institutional investors. A live webcast and a 90-day archived replay will be broadcast via the company's investor relations portal.

While the press release outlines a standard corporate itinerary, the subtext of this European summit is far more critical. Following the discontinuation of its former lead depression candidate, esmethadone, Relmada has aggressively repositioned its operational framework. The company is now channeling its resources into two highly differentiated assets: NDV-01 for non-muscle invasive bladder cancer (NMIBC) and sepranolone for Prader-Willi syndrome (PWS). The Jefferies conference provides a global platform for management to validate this new clinical infrastructure and prove that their engineered solutions can overcome significant biological bottlenecks.

Re-engineering the Delivery Infrastructure

In the realm of oncology, the efficacy of a therapeutic is often limited by the physical infrastructure of its delivery. Non-muscle invasive bladder cancer presents a unique logistical challenge. The current standard of care—intravesical Bacillus Calmette-Guérin (BCG)—is effective for some, but many patients become unresponsive or intolerant, leaving them with limited, highly invasive options. Conventional combinations of gemcitabine and docetaxel have been utilized in academic settings, but their administration is operationally complex and burdensome for both clinics and patients.

Relmada's NDV-01 is designed to overhaul this delivery network. As a sustained-release, intravesical formulation of gemcitabine and docetaxel, NDV-01 utilizes a proprietary soft matrix technology. This matrix prolongs the bladder's exposure to the chemotherapy agents, ensuring consistent, localized drug delivery while minimizing systemic toxicity. More importantly, it is designed for in-office administration in under five minutes, requiring no anesthesia or specialized equipment. It is a prime example of how optimizing the physical delivery mechanism can fundamentally alter a treatment's viability.

The clinical data supporting this architecture is compelling. Interim 12-month data from an ongoing Phase 2 study demonstrated a durable 76% complete response (CR) rate in high-risk NMIBC patients, and an 80% CR rate in BCG-unresponsive patients. Crucially, no patients progressed to muscle-invasive disease or required radical cystectomy, and the treatment was remarkably well-tolerated with no Grade 3 or higher treatment-related adverse events reported.

At the London conference, institutional analysts will be closely monitoring updates on the Phase 3 RESCUE registrational program. This program encompasses two independent approval pathways: the REL-NDV01-303 trial for BCG-unresponsive NMIBC, and the REL-NDV01-301 (BOOST) trial for adjuvant intermediate-risk NMIBC. With the U.S. Food and Drug Administration reportedly aligned on key study design elements, Relmada is expected to submit the NDV-01 Investigational New Drug (IND) application by year-end 2026, triggering the initiation of the Phase 3 program.

Modulating Neural Networks: The Sepranolone Bet

Beyond oncology, Relmada is applying its strategic focus to the intricate signaling networks of the central nervous system. Sepranolone, the company's second lead candidate, targets compulsivity-related disorders by modulating GABAA receptor activity. Acquired from Asarina Pharma, sepranolone is a synthetic analog of an antagonist of allopregnanolone (ALLO), a neurosteroid deeply embedded in the regulation of anxiety, compulsivity, and appetite.

By selectively counteracting the maladaptive effects of ALLO, sepranolone aims to normalize GABAA receptor signaling without triggering off-target CNS effects. This precision approach is currently being directed toward Prader-Willi syndrome (PWS), a rare genetic disorder characterized by severe hyperphagia (insatiable hunger) and debilitating compulsive behaviors. Current treatments for PWS merely manage symptoms; they do not address the underlying neurobehavioral pathology.

Sepranolone enters this space with a robust safety profile, having been administered to over 335 patients in previous clinical trials for conditions like Tourette syndrome and premenstrual dysphoric disorder. Relmada's immediate milestone is the submission of an IND for sepranolone by the end of 2026, paving the way for a Phase 2 proof-of-concept study in PWS. For investors in London, the timeline and design of this Phase 2 trial will be a focal point, as it represents a high-upside venture into a rare disease market with profound unmet needs.

The Financial Runway: Capital as the Ultimate Network

No clinical architecture can survive without a robust network of capital. In the current macroeconomic environment, where clinical-stage biotech companies are routinely punished for high burn rates and dwindling reserves, Relmada's financial infrastructure is a notable outlier.

As of June 30, 2026, the company reported cash, cash equivalents, and short-term investments totaling $217.7 million—a significant expansion from the $93.0 million reported at the end of 2025. This capitalization provides a projected funding runway through 2029, effectively insulating Relmada from the immediate need for dilutive financing. This runway is strategically calculated to cover the completion of the NDV-01 Phase 3 RESCUE program and the advancement of sepranolone.

However, maintaining this infrastructure requires careful capital allocation. For the second quarter of 2026, net cash used in operating activities was $9.6 million, up from $6.4 million in the prior year. Research and development expenses climbed to $8.4 million, reflecting the increased costs associated with scaling up NDV-01 and sepranolone studies, alongside manufacturing and drug storage requirements. With a net cash per share of approximately $1.92 at the end of Q2, management's objective at Jefferies will be to demonstrate that this capital burn is directly translating into tangible clinical milestones and long-term shareholder value.

Navigating a Crowded Ecosystem

The transition from clinical development to commercial viability requires navigating a complex and highly competitive ecosystem. In the NMIBC space, Relmada is not operating in a vacuum. The market features formidable competitors, including Merck's immune checkpoint inhibitor Keytruda, Ferring Pharmaceuticals' gene therapy Adstiladrin, and ImmunityBio's Anktiva. Furthermore, Johnson & Johnson's Inlexzo offers a direct competitive threat by delivering gemcitabine for BCG-unresponsive NMIBC with carcinoma in situ.

Relmada's strategy relies on structural differentiation. By combining both gemcitabine and docetaxel in a proprietary sustained-release matrix that can be administered in a standard office visit, NDV-01 aims to bypass the systemic and operational bottlenecks that hinder existing therapies.

To reinforce this commercial infrastructure, Relmada recently appointed Bipin Dalmia, PhD, MBA, as Chief Business Officer. Bringing extensive experience in uro-oncology and having previously led the US launch of the first FDA-approved intravesical gene therapy for NMIBC, Dalmia's integration into the leadership team signals a clear intent to prepare for late-stage development and commercialization. As Traversa and Shenouda take the stage in London, their narrative will likely center on this precise alignment of biological innovation, strategic capital deployment, and commercial readiness.